← Back to codex

Kisspeptin-54

Aliases: KP-54 · Metastin

Last verified: 2026-09-23

Clinical trialsLimited evidencePeptidesLow interest

The short version

Full-length kisspeptin (54 aa) — a more potent GnRH stimulator than KP-10; clinically studied for reproductive disorders and HSDD. Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Imperial College studies in reproduction and sexual function. Status: in clinical trials. Investigational.

Identity & type

Molecular type
peptide
Origin
Full-length kisspeptin (54 aa) — a more potent GnRH stimulator than KP-10; clinically studied for reproductive disorders and HSDD.

Mechanism of action

KISS1R agonism on GnRH neurons.

not confirmed in humans

Dosing & routes

Official / clinical context

No approved official document exists for Kisspeptin-54. Any protocols mentioned are to be read as information, not as a recommendation.

Regulator-approved labeling and published study designs — never a recommendation.

Community-reported practice

Trials: IV/SC boluses in nmol ranges. Investigational: a stronger GnRH pulse than KP-10; the community experiments with reproductive-axis "resets".

Unverified self-reports. Not medical advice. Not endorsement.

Expected effects (community)

Investigational: a stronger GnRH pulse than KP-10; the community experiments with reproductive-axis "resets".

Protocol — official vs community

Official / label

No approved protocol exists — clinical-stage investigational agent. Imperial College studies used IV or SC boluses and short infusions in nmol/kg ranges for reproductive and sexual-function endpoints.

Duration: Single-dose or short-infusion study designs; no chronic protocol has been tested.

Kisspeptin-54 was well tolerated across these small studies, which is the strongest statement the human data supports — it was studied in dozens of participants, not thousands.

Community (anecdotal)

Structured protocol data for this entry is coming.

Human evidence

Human data are limited: small trials or case-series reports exist, without large randomized studies. Imperial College studies in reproduction and sexual function.

Preclinical evidence

Imperial College studies in reproduction and sexual function.

Known risks

  • Well tolerated.characterized
  • Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical

Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.

Unknowns & evidence gaps

  • Long-term human safety
  • Optimal dose and pharmacokinetics

Frequently asked questions

References

Systematic references are being expanded; verify sources directly before any decision.